# Cover Letter Attachments for Controlled Correspondences and ANDA Submissions:  Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/cover-letter-attachments-for-controlled-correspondences-and-anda-submissions-guidance-for-industry/2b16776c-c5b5-4985-bb58-5746b2e77188

> FDA guidance document: Cover Letter Attachments for Controlled Correspondences and ANDA Submissions:  Guidance for Industry. Issue date: June 05, 2023. Get complete insights and analysis.

---

## Details

- Title: Cover Letter Attachments for Controlled Correspondences and ANDA Submissions:  Guidance for Industry
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2023-06-05
- Last Changed: 2023-06-05
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2021-D-0861">FDA-2021-D-0861</a>

## Related Documents

- [Post-Warning Letter Meetings Under GDUFA](https://www.globalkeysolutions.net/guidances/guidance-document/post-warning-letter-meetings-under-gdufa/4176915b-4275-4264-96ff-88a64a4f46e7)
- [Controlled Correspondence Related to Generic Drug Development](https://www.globalkeysolutions.net/guidances/guidance-document/controlled-correspondence-related-to-generic-drug-development/55babf6e-6cea-4e6c-80f6-3892feff9aab)
- [Nonclinical Evaluation of the Immunotoxic Potential of Pharmaceuticals](https://www.globalkeysolutions.net/guidances/guidance-document/nonclinical-evaluation-of-the-immunotoxic-potential-of-pharmaceuticals/160dff53-faf3-4095-b37e-414e108646cf)